Search

Your search keyword '"de Castro, J."' showing total 2,291 results
Start Over Author "de Castro, J."
2,291 results on '"de Castro, J."'

53. Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

Author

Isla D, De Castro J, Juan O, Grau S, Orofino J, Gordo R, Rubio-Terrés C, and Rubio-Rodríguez D

Subjects
adverse event, afatinib, cost-analysis, erlotinib, non-small-cell lung cancer., Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950
Abstract

Dolores Isla,1 Javier De Castro,2 Oscar Juan,3 Santiago Grau,4 Javier Orofino,5 Rocío Gordo,5 Carlos Rubio-Terrés,6 Darío Rubio-Rodríguez6 1Medical Oncology Department, Clinical Universitary Hospital Lozano Blesa, Zaragoza, 2Medical Oncology Department, Universitary Hospital La Paz, Madrid, 3Medical Oncology Department, Universitary and Polytechnic Hospital La Fe, Valencia, 4Pharmacy Department, Del Mar Hospital, Barcelona, 5Roche Farma, S.A., Health Economics, 6Health Value, Health Economics, Madrid, Spain Objectives: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are an established treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutation. According to published meta-analyses, no significant efficacy differences have been demonstrated between erlotinib and afatinib. However, the incidence of EGFR–TKI-related adverse events (AEs) was lower with erlotinib. This study compares the cost of management of the AEs associated with these two drugs from the perspective of the Spanish National Health System (NHS).Methods: The frequency of AEs was established from a recently published meta-analysis. In Spain, the daily cost of both drugs can be considered similar; as a result, only the costs of management of the AEs were considered. Costs and resource utilization in the management of the AEs were estimated by a panel of Spanish oncologists and from studies previously carried out in Spain. A probabilistic analysis was performed based on a Monte Carlo simulation.Results: The model generated 1,000 simulations. The total cost per patient treated with erlotinib and afatinib was €657.44 and €1,272.15, respectively. With erlotinib, the cost per patient and per AE of grades ≤2 and ≥3 was €550.86 and €106.58, respectively, whereas the cost with afatinib was €980.63 and €291.52, respectively. The reduction in the number of AEs with erlotinib could avoid a mean cost for the NHS of €614.71 (95% CI: €342.57–881.29) per patient.Conclusion: In advanced EGFR mutation-positive NSCLC patients, first-line treatment with erlotinib could reduce health care costs for the NHS, due to a decrease in the AE rate compared with afatinib. In long-term treatments, the avoidance of complications and the lowering of costs associated with the management of AEs are relevant factors that contribute to the sustainability of the health system. Keywords: adverse event, afatinib, cost analysis, erlotinib, non-small cell lung cancer

Published
2016

57. A consensus statement on the gender perspective in lung cancer

Author

Isla, D., Majem, M., Viñolas, N., Artal, A., Blasco, A., Felip, E., Garrido, P., Remón, J., Baquedano, M., Borrás, J. M., Die Trill, M., García-Campelo, R., Juan, O., León, C., Lianes, P., López-Ríos, F., Molins, L., Planchuelo, M. Á., Cobo, M., Paz-Ares, L., Trigo, J. M., and de Castro, J.

Published
2017
Full Text
View/download PDF

58. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

Author

De Castro, J., González-Larriba, J. L., Vázquez, S., Massutí, B., Sanchez-Torres, J. M., Dómine, M., Garrido, P., Calles, A., Artal, A., Collado, R., García, R., Sereno, M., Majem, M., Macías, J. A., Juan, O., Gómez-Codina, J., Hernández, B., Lázaro, M., Ortega, A. L., Cobo, M., Trigo, J. M., Carcereny, E., Rolfo, C., Macia, S., Muñoz, J., Diz, P., Méndez, M., Rosillo, F., Paz-Ares, L., Cardona, J. V., and Isla, D.

Published
2017
Full Text
View/download PDF

59. EP.13A.05 Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

Author

de Castro, J., Cobo Dols, M., Dómine Gómez, M., Moreno Vega, A., Ponce Aix, S., Arriola, E., Carcereny, E., Majem, M., Huidobro Vence, G., Esteban González, E., Fuentes Pradera, J., Ortega Granados, A.L., Guillot Morales, M., Massuti Sureda, B., Fernández Núñez, N., Provencio, M., González-Mancha, N., Fajardo, C.A., Lerones, N., and García Campelo, R.

Published
2024
Full Text
View/download PDF

60. P1.13A.11 Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study.

Author

García-Campelo, R., Dómine Gómez, M., de Castro, J., Moreno Vega, A., Ponce Aix, S., Arriola, E., Carcereny, E., Majem, M., Huidobro Vence, G., Esteban González, E., Fuentes Pradera, J., Granados, A.L. Ortega, Guillot Morales, M., Massuti Sureda, B., Fernández Núñez, N., Provencio, M., González-Mancha, N., Fajardo, C.A., Lerones, N., and Cobo Dols, M.

Published
2024
Full Text
View/download PDF

61. EE495 Cost-Effectiveness Analysis of Adjuvant Atezolizumab Versus Best Supportive Care in the Treatment of Patients With Resectable Early-Stage Non-Small Cell Lung Cancer and PD-L1≥50% Expression

Author

Escudero, V, primary, Collado, R, additional, de Castro, J, additional, Insa, A, additional, Martínez, A, additional, Fernández, E, additional, Sullivan, I, additional, Flores, A, additional, Arrabal, N, additional, Carcedo, D, additional, and Manzaneque, A, additional

Published
2022
Full Text
View/download PDF

63. Basal characteristics of the prospective spanish immunotherapy registry of cardiovascular toxicity: SIR-CVT

Author

Zatarain-Nicolas, E, primary, Perez-Ramirez, S, additional, De Castro, J, additional, Martin-Garcia, A, additional, Del Barco, E, additional, Mesa Rubio, D, additional, De La Haba, J, additional, Martinez Monzonis, M A, additional, Aguin Losada, S, additional, Lozano Palencia, T, additional, Martinez-Banaclocha, N, additional, Gomez-Rubin, M C, additional, Cortez-Castedo, P, additional, Martin, P, additional, and Lopez-Fernandez, T, additional

Published
2022
Full Text
View/download PDF

64. P3.08E.04 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials

Author

Martínez-Toledo, C., Sierra, B., Molina-Alejandre, M., Casarrubios, M., Calvo, V., Nadal, E., García Campelo, M.R., Martínez-Martí, A., Garrido, A., Massutí, B., Insa, A., De Castro, J., Dómine, M., González-Larriba, J.L., Majem, M., Ponce, S., Barneto, I., Aguilar, A., Martín-López, J., Provencio, M., and Cruz- Bermúdez, A.

Published
2024
Full Text
View/download PDF

66. Neandertal roots: Cranial and chronological evidence from Sima de los Huesos

Author

Arsuaga, J. L., Martínez, I., Arnold, L. J., Aranburu, A., Gracia-Téllez, A., Sharp, W. D., Quam, R. M., Falguères, C., Pantoja-Pérez, A., Bischoff, J., Poza-Rey, E., Parés, J. M., Carretero, J. M., Demuro, M., Lorenzo, C., Sala, N., Martinón-Torres, M., García, N., de Velasco, A. Alcázar, Cuenca-Bescós, G., Gómez-Olivencia, A., Moreno, D., Pablos, A., Shen, C.-C., Rodríguez, L., Ortega, A. I., García, R., Bonmatí, A., de Castro, J. M. Bermúdez, and Carbonell, E.

Published
2014

69. Measles Aerosol Vaccination

Author

Valdespino-Gómez, J. L., de Lourdes Garcia-Garcia, M., Fernandez-de-Castro, J., Henao-Restrepo, A. M., Bennett, J., Sepulveda-Amor, J., Compans, R. W., editor, Cooper, M. D., editor, Honjo, T., editor, Koprowski, H., editor, Melchers, F., editor, Oldstone, M. B. A., editor, Olsnes, S., editor, Vogt, P. K., editor, Wagner, H., editor, and Plotkin, Stanley A., editor

Published
2006
Full Text
View/download PDF

71. Design of a Competitive and Collaborative Learning Strategy in a Communication Networks Course

Author

Regueras, L. M., Verdu, E., Verdu, M. J., and de Castro, J. P.

Abstract

In this paper, an educational methodology based on collaborative and competitive learning is proposed. The suggested approach has been successfully applied to an undergraduate communication networks course, which is part of the core curriculum of the three-year degree in telecommunications engineering at the University of Valladolid in Spain. This methodology is supported by two tools: the Moodle wiki for the collaborative part and a competitive learning tool called QUESTOURnament, which has been created by the authors to encourage the development of students' inquiry, documentation, and critical analysis skills while raising the level of involvement and communication between students and teachers. This paper describes how the collaborative and competitive approaches were combined and how the activities were ordered in phases. This educational proposal has been validated with academic outcomes and students' feedback. (Contains 6 tables and 2 figures.)

Published
2011
Full Text
View/download PDF

72. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study

Author

Provencio, M., primary, Serna, R., additional, Nadal, E., additional, Glez Larriba, J.L., additional, Martínez-Martí, A., additional, Bernabé, R., additional, Bosch-Barrera, J., additional, Garcia Benito, C., additional, Calvo, V., additional, Insa, A., additional, Ponce, S., additional, Reguart, N., additional, De Castro, J., additional, Massutí, B., additional, Palmero, R., additional, Aguado de la Rosa, C., additional, Mosquera, J., additional, Cobo, M., additional, Aguilar, A., additional, López Vivanco, G., additional, Camps, C., additional, Hernando Trancho, F., additional, López Castro, R., additional, Moran, T., additional, Barneto, I., additional, Rodríguez-Abreu, D., additional, and Romero, A., additional

Published
2022
Full Text
View/download PDF

73. EP08.02-131 Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program

Author

Bernabé-Caro, R., primary, García-Campelo, R., additional, Garrido, P., additional, Palmero, R., additional, Artal, Á., additional, Bayona, C., additional, Rodríguez-Abreu, D., additional, López-Brea, M., additional, Paredes, A., additional, Vicente, D., additional, Sánchez Torres, J.M., additional, Majem, M., additional, Diz, P., additional, Gordo, R., additional, Coca, M., additional, and de Castro, J., additional

Published
2022
Full Text
View/download PDF

74. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial

Author

Romero, A., primary, Serna, R., additional, Nadal, E., additional, Larriba, J.L. Glez, additional, Martínez-Martí, A., additional, Bernabé, R., additional, Bosch-Barrera, J., additional, Fernandez, A. Garrido, additional, Calvo, V., additional, Insa, A., additional, Ponce, S., additional, Reguart, N., additional, De Castro, J., additional, Massutí, B., additional, Palmero, R., additional, Aguado de la Rosa, C., additional, Mosquera, J., additional, Cobo, M., additional, Aguilar, A., additional, Vivanco, G. López, additional, Camps, C., additional, Trancho, F. Hernando, additional, Castro, R. Lopez, additional, Moran, T., additional, Barneto, I., additional, Rodríguez-Abreu, D., additional, Cruz, A., additional, and Provencio, M., additional

Published
2022
Full Text
View/download PDF

75. 989P Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)

Author

Awad, M., primary, Pelizzari, G., additional, Stevenson, J.P., additional, Majem Tarruella, M., additional, Ferreira, C.G.M., additional, Petty, W.J., additional, Arriola, E., additional, de Castro, J., additional, Morbeck, I., additional, Bauman, J.R., additional, Toschi, L., additional, Zer, A., additional, Metro, G., additional, Kalmadi, S., additional, Azkárate Martínez, A., additional, Xia, C., additional, Meloni, A., additional, Obiozor, C., additional, Maimon, N., additional, and Novello, S., additional

Published
2022
Full Text
View/download PDF

76. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC

Author

Hernandez, S., primary, Rodriguez Carrillo, J.L., additional, Caminoa, A., additional, Benito, A., additional, Martinez, R., additional, Alonso, M., additional, Clave, S., additional, Arriola, E., additional, Esteban-Rodriguez, I., additional, De Castro, J., additional, Sansano, I., additional, Felip, E., additional, Abdulkader, I., additional, Garcia, J., additional, Rojo, F., additional, Domine, M., additional, Teixido, C., additional, Reguart, N., additional, Compañ, D., additional, Insa, A., additional, Mancheño, N., additional, Palanca, S., additional, Juan, O., additional, Baixeras, N., additional, Nadal, E., additional, Cebollero, M., additional, Calles, A., additional, Martin, P., additional, Salas, C., additional, Provencio, M., additional, Aranda, I., additional, Massuti, B., additional, Lopez-Vilaro, L., additional, Majem, M., additional, Garrido, P., additional, Paz-Ares, L., additional, Lopez-Rios, F., additional, and Conde, E., additional

Published
2022
Full Text
View/download PDF

78. Nefrectomía parcial y radical laparoscópica en tumores renales cT1. Análisis comparativo de complicaciones y supervivencia

Author

Luis-Cardo, A., primary, Herranz-Amo, F., additional, Rodríguez-Cabero, M., additional, Quintana-Álvarez, R., additional, Esteban-Labrador, L., additional, Rodríguez-Fernández, E., additional, Mayor-de Castro, J., additional, Barbas-Bernardos, G., additional, Ramírez-Martín, D., additional, and Hernández-Fernández, C., additional

Published
2022
Full Text
View/download PDF

79. MobiS: A Solution for the Development of Secure Applications for Mobile Devices

Author

Viana, W., Filho, B., Magalhães, K., Giovano, C., de Castro, J., Andrade, R., Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Dough, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, de Souza, José Neuman, editor, Dini, Petre, editor, and Lorenz, Pascal, editor

Published
2004
Full Text
View/download PDF

82. Cancer pain

Author

De Castro, J., Meynadier, J., Zenz, M., De Castro, J., Meynadier, J., and Zenz, M.

Published
1991
Full Text
View/download PDF

83. Obstetrics

Author

De Castro, J., Meynadier, J., Zenz, M., De Castro, J., Meynadier, J., and Zenz, M.

Published
1991
Full Text
View/download PDF

92. Drugs

Author

De Castro, J., Meynadier, J., Zenz, M., De Castro, J., Meynadier, J., and Zenz, M.

Published
1991
Full Text
View/download PDF

93. Side effects

Author

De Castro, J., Meynadier, J., Zenz, M., De Castro, J., Meynadier, J., and Zenz, M.

Published
1991
Full Text
View/download PDF

99. Revision of TD1 and TD2 stratigraphic sequence of Gran Dolina cave (Sierra de Atapuerca, Spain)

Author

Universitat Rovira i Virgili, Campana, I; Benito-Calvo, A.; Perez-Gonzalez, A.; Alvaro-Gallo, A.; Miguens-Rodriguez, L.; Iglesias-Cibanal, J.; Bermudez de Castro, J. M.; Carbonell, E., Universitat Rovira i Virgili, and Campana, I; Benito-Calvo, A.; Perez-Gonzalez, A.; Alvaro-Gallo, A.; Miguens-Rodriguez, L.; Iglesias-Cibanal, J.; Bermudez de Castro, J. M.; Carbonell, E.

Abstract

Gran Dolina is a cavity infilled by at least 25 m of Pleistocene sediments divided into 12 lithostratigraphic units and 19 sedimentary facies. These sedimentary facies have been divided into allochthonous facies, defined as sediment inputs from the outside, and autochthonous facies, defined as sediments generated within the karst; but this division has been challenged in recent works. In this study, TD1 and TD2 units of Gran Dolina have been detailed studied and the use of autochthonous facies has been assessed. For that purpose, we have studied the stratigraphic excavation profile, combining field observation with laboratory sedimentary analysis (sieving, laser diffraction, and XRD) to characterize the texture and structure of the sediments. Based on these studies, a total of 8 sedimentary facies have been identified. Consequently, TD1 unit has been separated into two sub-units and 13 layers, while the TD2 unit has been divided into three sub-units. The facies associations indicate a succession of phreatic and vadose phases that would define together epiphreatic conditions inside the cave, related to the transition between Arlanzon valley terraces T3 and T4. Interior facies (and entrance facies for allochthonous facies) is proposed to define Gran Dolina's sediments since the facies analyses indicate transport by underground flows.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results